Company Filing History:
Years Active: 2020-2023
Title: Emil F Michelotti: Innovator in ASCT2-Binding Molecules
Introduction
Emil F Michelotti is a notable inventor based in Gaithersburg, MD (US). He has made significant contributions to the field of biotechnology, particularly in the development of ASCT2-binding molecules. With a total of 2 patents, his work focuses on innovative solutions for diagnosing and treating diseases characterized by ASCT2 overexpression.
Latest Patents
Michelotti's latest patents include the development of ASCT2-binding molecules, such as anti-ASCT2 antibodies and their antigen-binding fragments. These molecules are designed to be conjugated to cytotoxic drugs, forming ASCT2 antibody-drug conjugates (ADCs). The anti-ASCT2 antibodies can be derived from hybridoma technology, resulting in murine monoclonal antibodies and their humanized versions. These binding molecules specifically target cells that express ASCT2 and can be internalized into these cells. His patents also provide methods for diagnosing and treating various diseases, including certain types of cancer, through the use of ASCT2 ADCs.
Career Highlights
Emil F Michelotti has established a successful career at Medimmune Limited, where he continues to innovate in the field of biotechnology. His research has the potential to significantly impact cancer treatment and improve patient outcomes.
Collaborations
Michelotti has collaborated with notable colleagues, including Nabendu Pore and Martin Borrok, III. These partnerships have contributed to the advancement of his research and the development of new therapeutic strategies.
Conclusion
Emil F Michelotti is a distinguished inventor whose work on ASCT2-binding molecules is paving the way for innovative cancer treatments. His contributions to biotechnology exemplify the importance of research and collaboration in advancing medical science.